Search

Your search keyword '"Hamner, Mark B"' showing total 4 results
Start Over Author "Hamner, Mark B" Publication Year Range Last 3 years
4 results on '"Hamner, Mark B"'

3. Post-traumatic stress disorder: the role of the amygdala and potential therapeutic interventions -- a review.

Author

Davis, Lori L. and Hamner, Mark B.

Subjects
POST-traumatic stress disorder, AMYGDALOID body, EVIDENCE-based psychotherapy, NEURAL circuitry, ION channels
Abstract

Introduction: Post-traumatic stress disorder (PTSD) is a psychiatric disorder triggered by exposure to a life-threatening or sexually violent traumatic event, and is characterized by symptoms involving intrusive re-experiencing, persistent avoidance of associated stimuli, emotional and cognitive disturbances, and hyperarousal for long periods after the trauma has occurred. These debilitating symptoms induce occupational and social impairments that contribute to a significant clinical burden for PTSD patients, and substantial socioeconomic costs, reaching approximately $20,000 dollars per individual with PTSD each year in the US. Despite increased translational research focus in the field of PTSD, the development of novel, effective pharmacotherapies for its treatment remains an important unmet clinical need. Observations: In this review, we summarize the evidence implicating dysfunctional activity of the amygdala in the pathophysiology of PTSD. We identify the transient receptor potential canonical (TRPC) ion channels as promising drug targets given their distribution in the amygdala, and evidence from animal studies demonstrating their role in fear response modulation. We discuss the evidence-based pharmacotherapy and psychotherapy treatment approaches for PTSD. Discussion: In view of the prevalence and economic burden associated with PTSD, further investigation is warranted into novel treatment approaches based on our knowledge of the involvement of brain circuitry and the role of the amygdala in PTSD, as well as the potential added value of combined pharmacotherapy and psychotherapy to better manage PTSD symptoms. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

4. Effect of Pharmacogenomic Testing for Drug-Gene Interactions on Medication Selection and Remission of Symptoms in Major Depressive Disorder

Author

Oslin, David W., Lynch, Kevin G., Shih, Mei-Chiung, Ingram, Erin P., Wray, Laura O., Chapman, Sara R., Kranzler, Henry R., Gelernter, Joel, Pyne, Jeffrey M., Stone, Annjanette, DuVall, Scott L., Lehmann, Lisa Soleymani, Thase, Michael E., Aslam, Muhammad, Batki, Steven L., Bjork, James M., Blow, Frederic C., Brenner, Lisa A., Chen, Peijun, Desai, Shivan, Dieperink, Eric W., Fears, Scott C., Fuller, Matthew A., Goodman, Courtney S., Graham, David P., Haas, Gretchen L., Hamner, Mark B., Helstrom, Amy W., Hurley, Robin A., Icardi, Michael S., Jurjus, George J., Kilbourne, Amy M., Kreyenbuhl, Julie, Lache, Daniel J., Lieske, Steven P., Lynch, Julie A., Meyer, Laurence J., Montalvo, Cristina, Muralidhar, Sumitra, Ostacher, Michael J., Paschall, Gayla Y., Pfeiffer, Paul N., Prieto, Susana, Przygodzki, Ronald M., Ranganathan, Mohini, Rodriguez-Suarez, Mercedes M., Roggenkamp, Hannah, Schichman, Steven A., Schneeweis, John S., Simonetti, Joseph A., Steinhauer, Stuart R., Suppes, Trisha, Umbert, Maria A., Vassy, Jason L., Voora, Deepak, Wiechers, Ilse R., and Wood, Amanda E.

Subjects
Male, Depressive Disorder, Major, Depression, Clinical Decision-Making, Remission Induction, Inappropriate Prescribing, General Medicine, Middle Aged, United States, Antidepressive Agents, Pharmacogenomic Testing, United States Department of Veterans Affairs, Treatment Outcome, Pharmacogenetics, Humans, Drug Interactions, Female, Original Investigation
Abstract

IMPORTANCE: Selecting effective antidepressants for the treatment of major depressive disorder (MDD) is an imprecise practice, with remission rates of about 30% at the initial treatment. OBJECTIVE: To determine whether pharmacogenomic testing affects antidepressant medication selection and whether such testing leads to better clinical outcomes. DESIGN, SETTING, AND PARTICIPANTS: A pragmatic, randomized clinical trial that compared treatment guided by pharmacogenomic testing vs usual care. Participants included 676 clinicians and 1944 patients. Participants were enrolled from 22 Department of Veterans Affairs medical centers from July 2017 through February 2021, with follow-up ending November 2021. Eligible patients were those with MDD who were initiating or switching treatment with a single antidepressant. Exclusion criteria included an active substance use disorder, mania, psychosis, or concurrent treatment with a specified list of medications. INTERVENTIONS: Results from a commercial pharmacogenomic test were given to clinicians in the pharmacogenomic-guided group (n = 966). The comparison group received usual care and access to pharmacogenomic results after 24 weeks (n = 978). MAIN OUTCOMES AND MEASURES: The co–primary outcomes were the proportion of prescriptions with a predicted drug-gene interaction written in the 30 days after randomization and remission of depressive symptoms as measured by the Patient Health Questionnaire–9 (PHQ-9) (remission was defined as PHQ-9 ≤ 5). Remission was analyzed as a repeated measure across 24 weeks by blinded raters. RESULTS: Among 1944 patients who were randomized (mean age, 48 years; 491 women [25%]), 1541 (79%) completed the 24-week assessment. The estimated risks for receiving an antidepressant with none, moderate, and substantial drug-gene interactions for the pharmacogenomic-guided group were 59.3%, 30.0%, and 10.7% compared with 25.7%, 54.6%, and 19.7% in the usual care group. The pharmacogenomic-guided group was more likely to receive a medication with a lower potential drug-gene interaction for no drug-gene vs moderate/substantial interaction (odds ratio [OR], 4.32 [95% CI, 3.47 to 5.39]; P

Published
2022

Catalog

Books, media, physical & digital resources
See catalog results